Montelukast does not affect exercise performance at subfreezing temperature in highly trained non-asthmatic endurance athletes
(2000) In International Journal of Sports Medicine 21(6). p.424-428- Abstract
- Anti-leukotriene therapy represents a new principle in asthma treatment. As elite athletes can have asthma, this double-blind, placebo-controlled, randomised cross-over study investigated the effect of 10 mg oral montelukast, a specific and potent cysteinyl leukotriene receptor antagonist, on physiological responses to submaximal and maximal aerobic exercise at -15 degrees C in 14 non-asthmatic highly trained endurance male athletes (maximal oxygen uptake [VO2 max] > 70 ml x kg(-1) x min(-1)). Heart rate, capillary blood lactate, minute ventilation with tidal volume and breathing frequency, respiratory exchange ratio and oxygen uptake were measured during the warm-up run of 10 min at 50%, runs of 10 min at 90% and 5 min at 80% VO2max,... (More)
- Anti-leukotriene therapy represents a new principle in asthma treatment. As elite athletes can have asthma, this double-blind, placebo-controlled, randomised cross-over study investigated the effect of 10 mg oral montelukast, a specific and potent cysteinyl leukotriene receptor antagonist, on physiological responses to submaximal and maximal aerobic exercise at -15 degrees C in 14 non-asthmatic highly trained endurance male athletes (maximal oxygen uptake [VO2 max] > 70 ml x kg(-1) x min(-1)). Heart rate, capillary blood lactate, minute ventilation with tidal volume and breathing frequency, respiratory exchange ratio and oxygen uptake were measured during the warm-up run of 10 min at 50%, runs of 10 min at 90% and 5 min at 80% VO2max, and a timed run to exhaustion. Spirometry was performed at baseline, at four hours after tablet ingestion, after warm-up and exercise at 80% VO2max, and in the post exercise period. Compared to placebo, montelukast did not increase baseline FEV1, have a beneficial effect on physiological performance variables, or increase the mean (SD) running time to exhaustion (montelukast: 332.3 [45.8] s, placebo: 340.1 [53.3] s, P = 0.22). These findings do not suggest the need for disallowing the use of this drug by asthmatic athletes. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1116644
- author
- Sue-Chu, M ; Sandsund, M ; Holand, B and Bjermer, Leif LU
- publishing date
- 2000
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Montelukast, leukotriene receptor antagonists, physical performance, endurance athletes
- in
- International Journal of Sports Medicine
- volume
- 21
- issue
- 6
- pages
- 424 - 428
- publisher
- Georg Thieme Verlag
- external identifiers
-
- pmid:10961518
- scopus:0033860413
- ISSN
- 0172-4622
- DOI
- 10.1055/s-2000-3838
- language
- English
- LU publication?
- no
- id
- c0e0ffe0-003d-41d1-b048-ae060b5c1b7c (old id 1116644)
- date added to LUP
- 2016-04-01 16:44:37
- date last changed
- 2022-03-15 02:39:01
@article{c0e0ffe0-003d-41d1-b048-ae060b5c1b7c,
abstract = {{Anti-leukotriene therapy represents a new principle in asthma treatment. As elite athletes can have asthma, this double-blind, placebo-controlled, randomised cross-over study investigated the effect of 10 mg oral montelukast, a specific and potent cysteinyl leukotriene receptor antagonist, on physiological responses to submaximal and maximal aerobic exercise at -15 degrees C in 14 non-asthmatic highly trained endurance male athletes (maximal oxygen uptake [VO2 max] > 70 ml x kg(-1) x min(-1)). Heart rate, capillary blood lactate, minute ventilation with tidal volume and breathing frequency, respiratory exchange ratio and oxygen uptake were measured during the warm-up run of 10 min at 50%, runs of 10 min at 90% and 5 min at 80% VO2max, and a timed run to exhaustion. Spirometry was performed at baseline, at four hours after tablet ingestion, after warm-up and exercise at 80% VO2max, and in the post exercise period. Compared to placebo, montelukast did not increase baseline FEV1, have a beneficial effect on physiological performance variables, or increase the mean (SD) running time to exhaustion (montelukast: 332.3 [45.8] s, placebo: 340.1 [53.3] s, P = 0.22). These findings do not suggest the need for disallowing the use of this drug by asthmatic athletes.}},
author = {{Sue-Chu, M and Sandsund, M and Holand, B and Bjermer, Leif}},
issn = {{0172-4622}},
keywords = {{Montelukast; leukotriene receptor antagonists; physical performance; endurance athletes}},
language = {{eng}},
number = {{6}},
pages = {{424--428}},
publisher = {{Georg Thieme Verlag}},
series = {{International Journal of Sports Medicine}},
title = {{Montelukast does not affect exercise performance at subfreezing temperature in highly trained non-asthmatic endurance athletes}},
url = {{http://dx.doi.org/10.1055/s-2000-3838}},
doi = {{10.1055/s-2000-3838}},
volume = {{21}},
year = {{2000}},
}